Posted by Michael Wonder on 22 Nov 2021
Intarcia Therapeutics takes one last shot at FDA approval
22 November 2021 - Its diabetes treatment twice rejected, the company is in the midst of a rarely used appeal process, and is awaiting the FDA’s verdict.
Intarcia Therapeutics, once among the most promising emerging companies in biotech, is taking a rarely used route to dispute not one, but two FDA rejections of its Type 2 diabetes treatment.
